TY - JOUR
T1 - Introduction
T2 - Addressing challenges in multiple myeloma management in an era of new therapeutics
AU - Jagannath, Sundar
PY - 2010/2
Y1 - 2010/2
N2 - Hematologists, oncologists, and other physicians can expect to encounter an increasing number of patients with multiple myeloma. Historically, multiple myeloma has been a difficult and frustrating disease, but since the reintroduction of thalidomide and the development of lenalidomide and bortezomib, outcomes have improved considerably. This supplement is part of a 3-supplement series planned at a roundtable discussion held in 2009, and this introduction discusses the articles in this supplement as well as those in earlier and later planned publications not included in JNCCN.
AB - Hematologists, oncologists, and other physicians can expect to encounter an increasing number of patients with multiple myeloma. Historically, multiple myeloma has been a difficult and frustrating disease, but since the reintroduction of thalidomide and the development of lenalidomide and bortezomib, outcomes have improved considerably. This supplement is part of a 3-supplement series planned at a roundtable discussion held in 2009, and this introduction discusses the articles in this supplement as well as those in earlier and later planned publications not included in JNCCN.
UR - http://www.scopus.com/inward/record.url?scp=77649133928&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2010.0111
DO - 10.6004/jnccn.2010.0111
M3 - Article
C2 - 20141669
AN - SCOPUS:77649133928
SN - 1540-1405
VL - 8
SP - S1-S3
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - SUPPL. 1
ER -